Eden, J.-S. et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat. Commun. 13, 2884 (2022).

CAS  Article  Google Scholar 

Li, Y. et al. Understanding the potential drivers for respiratory syncytial virus rebound during the coronavirus disease 2019 pandemic. J. Infect. Dis. 225, 957–964 (2022).

CAS  Article  Google Scholar 

Koutsakos, M., Wheatley, A. K., Laurie, K., Kent, S. J. & Rockman, S. Influenza lineage extinction during the COVID-19 pandemic? Nat. Rev. Microbiol. 19, 741–742 (2021).

CAS  Article  Google Scholar 

IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531–537 (1998).

Article  Google Scholar 

Hammitt, L. L. et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N. Engl. J. Med. 386, 837–846 (2022).

CAS  Article  Google Scholar 

McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592–598 (2013).

CAS  Article  Google Scholar 

Madhi, S. A. et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N. Engl. J. Med. 383, 426–439 (2020).

CAS  Article  Google Scholar 

Schmoele-Thoma, B. et al. Vaccine efficacy in adults in a respiratory syncytial virus challenge study. N. Engl. J. Med. 386, 2377–2386 (2022).

Article  Google Scholar 

Zhu, Q. et al. Prevalence and significance of substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization escape from antibody MEDI8897. J. Infect. Dis. 218, 572–580 (2018).

CAS  Article  Google Scholar 

Simões, E. A. F. et al. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin. Infect. Dis. 73, e4400–e4408 (2021).

Article  Google Scholar